A sub-analysis of the CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) trial demonstrated that anti-IL-1β therapy (canakinumab) significantly reduced cardiovascular events in patients with TET2-CH but not in those with CH driven by other mutations, including ASXL1 [47]. Here, TET2 is linked to cyclic hematopoiesis.